Feline Leukemia Virus (FeLV) in Cats — Management Guide

Practical, evidence-based guide to FeLV: what it is, how it's diagnosed (ELISA vs IFA vs PCR), treatment options, long-term care, vaccination, and household management.

Quick Overview

• What it is: Feline leukemia virus (FeLV) is a contagious retrovirus that infects cats and can cause immunosuppression, anemia, and certain cancers (most notably lymphoma and leukemia).
• Who's at risk: Unvaccinated cats, outdoor or free-roaming cats, kittens born to infected queens, cats in shelters or multi-cat households, and intact males are at higher risk.
• Prognosis: Variable. Some cats clear or control infection (regressive), some develop progressive infection with shortened life expectancy and higher disease risk. With good care, many FeLV-positive cats can live months to years; progressive infections historically carried median survival of months to a few years depending on disease manifestations.

This guide is for educational purposes. Always consult your veterinarian for diagnosis and treatment.

Pathophysiology (explained simply)

FeLV is a gammaretrovirus transmitted mainly by close contact: saliva (mutual grooming, bite wounds), nasal secretions, and, less commonly, in utero or via milk. After entry, the virus replicates in local lymphoid tissues and may spread through the blood (viremia). If the virus infects and replicates in bone marrow stem cells, persistent (progressive) infection results, with lifelong antigenemia and higher disease risk. In some cats the immune response suppresses replication and viral integration (regressive infection) — provirus may remain in cells but active viral production is low or absent.

Key consequences:

• Immunosuppression → more bacterial, viral, and fungal secondary infections
• Bone marrow suppression → non-regenerative anemia, cytopenias
• Oncogenesis → lymphoma, leukemia, other tumors

Breed-specific risk factors and prevalence

FeLV prevalence varies by geography and population (shelter vs owned cats). There is no strong, consistent breed predisposition; infection correlates more with lifestyle (outdoor access, multi-cat environments) than breed. Some regional studies have reported higher rates in certain populations (e.g., purebred cats in particular localities), but overall breed alone is not a reliable predictor. Young cats (kittens) are especially susceptible to progressive infection.

Clinical signs, stages and grading

Stages/variants of FeLV infection

• Abortive infection: Infection is cleared before systemic spread — cat remains antigen-negative.
• Regressive infection: Initial viremia occurs but is controlled by the immune system. The virus integrates as provirus but active replication is low; cats are often antigen-negative on repeated testing but can intermittently reactivate.
• Progressive infection: Persistent viremia with bone marrow infection and ongoing antigenemia. These cats are more likely to develop FeLV-related disease and transmit virus.
• Focal/atypical infection: Localized viral replication (rare) with variable test results.

• Recurrent or severe infections (upper respiratory, skin, urinary)
• Poor coat condition, weight loss
• Lethargy, inappetence
• Pale mucous membranes (anemia)
• Enlarged lymph nodes, breathing difficulty (mediastinal lymphoma)
• Oral disease, stomatitis
• Neurologic signs, reproductive failure

• Lymphoma (especially mediastinal in young cats) and leukemia
• Non-regenerative and regenerative anemia (including aplastic or immune-mediated)
• Secondary infections due to immunosuppression
• Stomatitis, oral disease

Diagnostic approach: tests, imaging, referral

Testing basics

• ELISA (point-of-care antigen test): Detects viral p27 antigen in whole blood, serum or plasma. High sensitivity for antigenemia; commonly used as an initial screening test. A positive ELISA indicates the presence of circulating viral antigen but does not by itself determine progressive vs regressive infection.
• IFA (immunofluorescence assay): Detects viral antigen inside circulating white blood cells or bone marrow cells. A positive IFA generally indicates bone marrow infection and therefore progressive, persistent infection.
• PCR (provirus/viral RNA testing): Molecular assays detect proviral DNA or viral RNA and can be useful when ELISA/IFA results are discordant, to detect regressive infections, or to confirm infection status. PCR may detect provirus in regressive infections even when antigen is absent.

• Screen with a validated ELISA in any new, sick, or at-risk cat.
• If ELISA positive, confirm with IFA (if available) or PCR. If IFA is positive, progressive infection is likely. If IFA is negative, perform PCR or repeat ELISA in 6–8 weeks to determine outcome (regressive vs early infection).
• Kittens: maternal factors and timing matter — retest kittens at 8–12 weeks and again after 12 weeks if exposure suspected.

• CBC and chemistry: evaluate for anemia, cytopenias, organ dysfunction.
• Thoracic/abdominal imaging (radiographs, ultrasound): evaluate for lymphoma, organomegaly, or secondary disease.
• Bone marrow aspirate/biopsy: if unexplained cytopenias or to stage disease.

• Suspected or confirmed FeLV-associated lymphoma/leukemia: oncology referral for staging and chemotherapy planning.
• Complicated anemia or transfusion needs: internal medicine or specialty referral.
• Complex cases needing antiviral protocols or immunomodulatory therapy.

Treatment options

There is no guaranteed cure for FeLV. Management focuses on treating concurrent disease, reducing clinical signs, and supportive care. Specific interventions include:

Supportive and symptomatic care

• Aggressive treatment of secondary infections (appropriate antibiotics, antifungals, or antivirals when indicated).
• Dental care: treat stomatitis/periodontal disease; extractions if needed.
• Nutritional support, appetite stimulants, antiemetics.
• Hematologic support: blood transfusions for life-threatening anemia (crossmatch, blood typing, and monitoring). Use packed red blood cells; fresh whole blood in some situations.
• Pain control and palliative care as needed.

• Zidovudine (AZT, zidovudine): a nucleoside reverse transcriptase inhibitor used off-label in cats. Typical dosing concepts: 5–10 mg/kg orally every 8–12 hours (exact dosing and interval vary). AZT has been used to reduce viral replication and to treat FeLV-associated stomatitis and some clinical signs. Side effects include bone marrow suppression (monitor CBC regularly). Not all cats respond; discuss risks/benefits and monitoring with your veterinarian.
• Interferons: Recombinant feline interferon-omega (available in some countries) or human interferon-alpha have been used to stimulate antiviral responses; evidence is mixed and treatments are costly. Benefits may be temporary.

• FeLV-associated lymphoma/leukemia: chemotherapy protocols (COP, CHOP, or others) can produce remission and palliation. FeLV-positive lymphoma typically has a less favorable prognosis than FeLV-negative lymphoma but some cats respond to therapy. Oncologist consultation is recommended.

• Immunosuppressive or immunomodulatory drugs may be used carefully (e.g., for immune-mediated anemia), balancing infection risks.

• AZT and interferon therapies produce variable responses; some cats improve clinically and hematologically, others do not. No antiviral therapy guarantees viral clearance in progressive infection.
• Chemotherapy can induce remission in some FeLV-associated lymphomas, but median survival is generally shorter than in FeLV-negative lymphoma (outcomes depend on tumor type, stage, and response).

Long-term management and monitoring

• Regular veterinary exams: every 3–6 months (or more often as advised) for clinical evaluation and monitoring.
• Bloodwork: baseline and periodic CBCs (to monitor for cytopenias, especially if on AZT), chemistry panels, and monitoring of secondary disease.
• Recheck FeLV testing: follow your veterinarian’s plan. Re-testing is useful if results were discordant or if clinical status changes.
• Preventive care: strict indoor lifestyle (to prevent exposure to other cats and protect others), parasite control, dental care, and nutrition.
• Keep vaccination current for other pathogens (e.g., rabies, calicivirus, panleukopenia) as advised by your veterinarian; vaccine responses may be reduced but vaccination against core diseases is still generally recommended.

• Ideally keep FeLV-positive cats separated from FeLV-negative cats. If mixing is unavoidable, minimize close contact that transfers saliva (grooming, shared food/water bowls). Best practice is to house FeLV+ cats with other FeLV+ cats or as single-cat households.
• New cats introduced to the household should be tested for FeLV before introduction.
• Disinfection: FeLV is an enveloped virus and is inactivated by common disinfectants (dilute bleach, 1:32 or 1:100 depending on product instructions, household disinfectants labeled for enveloped viruses).

Vaccination

• FeLV vaccines are available and recommended for cats at risk (outdoor cats, cats in multi-cat households with unknown FeLV status, kittens). They are not considered universally “core” for strictly indoor, single-household cats with no exposure risk.
• Typical schedule: start as kitten (often at 8–12 weeks), a booster 3–4 weeks later, then revaccination at 1 year; subsequent intervals depend on vaccine product (some are annual, some triennial). Follow vaccine label and veterinary advice.
• Vaccination reduces the risk of persistent infection but does not provide 100% protection.
• FeLV vaccination does not cause positive antigen tests (unlike some antibody-based tests for other diseases); a positive ELISA reflects viral antigen, not vaccination.
• Discuss injection-site sarcoma risk and vaccination site recommendations with your veterinarian; many clinics use distal limb or tail sites to allow surgical options if needed.

Prognosis and quality of life considerations

• Prognosis depends on stage (regressive vs progressive), clinical signs, and associated diseases.
• Regressive infections: many cats remain clinically healthy for years; risk of reactivation exists under immunosuppression.
• Progressive infections: higher risk of anemia, infections, and lymphoma; median survival times vary widely — historically often measured in months to a few years depending on disease burden and treatment.
• Quality of life should guide decisions: some FeLV-positive cats remain comfortable and can live meaningful lives with veterinary care; others with refractory infections, severe anemia, or progressive cancer may have poor quality of life and require humane euthanasia.

Living with FeLV — practical daily tips

• Keep the cat strictly indoors to protect others and to prevent exposure to hazards.
• Provide high-quality nutrition and monitor weight; small frequent meals if appetite is reduced.
• Maintain good dental hygiene and treat oral disease promptly.
• Avoid introducing new untested cats into the household; if you must, test first and isolate until results are confirmed.
• Reduce stress, which can precipitate disease reactivation: consistent routines, safe spaces, and environmental enrichment.
• Practice good hygiene when handling cats with open sores or infections; use gloves and wash hands. Disinfect bowls and litter boxes regularly.
• Keep a medical record and emergency plan (contacts, transfusion resources, oncologist referral if relevant).

When to See Your Vet Urgently

Seek immediate veterinary attention if your FeLV-positive cat develops any of the following:

• Sudden pallor or weakness (possible severe anemia)
• Difficulty breathing, open-mouth breathing, or coughing (possible mediastinal mass/lymphoma)
• Collapse, seizure, or disorientation
• Marked bleeding or petechiae
• High fever unresponsive to home care
• Rapid weight loss or prolonged inappetence

Key takeaways

• FeLV is a contagious retrovirus with variable outcomes: abortive, regressive, or progressive infection.
• Initial screening uses an ELISA antigen test; confirm positives with IFA or PCR, and retest kittens.
• There is no guaranteed cure. Management focuses on treating secondary disease, supportive care, and sometimes antiviral or immunomodulatory therapy (AZT, interferon—used off-label and monitored closely).
• Vaccination prevents many infections and is recommended for at-risk cats.
• Households should prevent spread by testing new cats, segregating FeLV+ cats from negatives, and maintaining an indoor lifestyle.

References and further reading

• AAFP/AACT Practice Guidelines: Feline Retrovirus Testing and Management (AAFP) — see your veterinarian’s resources and the AAFP website for the full guideline.
• Cornell Feline Health Center: Feline Leukemia Virus (FeLV) information page.
• Selected peer-reviewed sources and specialty texts on feline retroviruses and oncology (consult your veterinary team for copies relevant to your cat).

Frequently Asked Questions